Cancer Radiotherapie

metrics 2024

Shaping the future of cancer treatment with cutting-edge radiotherapy studies.

Introduction

Cancer Radiotherapie, published by Elsevier, is a respected academic journal dedicated to advancing the field of oncology and radiology through original research and comprehensive reviews. With an ISSN of 1278-3218 and an E-ISSN of 1769-6658, the journal serves as a vital platform for disseminating knowledge and innovation in cancer treatment methodologies, specifically focusing on radiotherapy. As of 2023, it holds a Category Quartile of Q3 in both Oncology and Radiology, Nuclear Medicine and Imaging, reflecting its significance within these domains amidst a competitive landscape. Despite its current rankings—205th out of 333 in Radiology and 269th out of 404 in Oncology—it continuously strives to build a reputable presence with contributions that push the boundaries of cancer therapy. Although open access options are not available, the journal is committed to ensuring that valuable insights reach healthcare professionals and researchers worldwide, contributing to improved patient outcomes and advancements in treatment efficacy.

Metrics 2024

SCIMAGO Journal Rank0.41
Journal Impact Factor1.50
Journal Impact Factor (5 years)1.20
H-Index36
Journal IF Without Self1.50
Eigen Factor0.00
Normal Eigen Factor0.26
Influence0.24
Immediacy Index0.20
Cited Half Life4.60
Citing Half Life7.40
JCI0.39
Total Documents2842
WOS Total Citations1225
SCIMAGO Total Citations7687
SCIMAGO SELF Citations2646
Scopus Journal Rank0.41
Cites / Document (2 Years)1.53
Cites / Document (3 Years)1.41
Cites / Document (4 Years)1.24

Metrics History

Rank 2024

Scopus

Radiology, Nuclear Medicine and Imaging in Medicine
Rank #205/333
Percentile 38.44
Quartile Q3
Oncology in Medicine
Rank #269/404
Percentile 33.42
Quartile Q3

IF (Web Of Science)

ONCOLOGY
Rank 259/322
Percentile 19.70
Quartile Q4
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Rank 124/204
Percentile 39.50
Quartile Q3

JCI (Web Of Science)

ONCOLOGY
Rank 246/322
Percentile 23.60
Quartile Q4
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Rank 144/204
Percentile 29.41
Quartile Q3

Quartile History

Similar Journals

Journal of Medical Imaging and Radiation Oncology

Empowering Research in Radiation Oncology and Imaging
Publisher: WILEYISSN: 1754-9477Frequency: 8 issues/year

Journal of Medical Imaging and Radiation Oncology, published by WILEY, is a pivotal resource in the fields of oncology and medical imaging. With an impact factor reflective of its commitment to advancing research, the journal has maintained a robust reputation since its inception in 2008 and continues to thrive through 2024. It is indexed with an insightful ranking, with a Q2 classification in Radiology, Nuclear Medicine and Imaging, affirming its importance in these disciplines. This journal not only serves as an open access platform, allowing extensive reach and accessibility, but also fosters a scholarly community dedicated to the innovation of imaging techniques and radiation oncology practices. As a key player in disseminating crucial findings and advancements, it appeals to researchers, clinicians, and students who aim to contribute to the evolving landscape of medical imaging and cancer treatment methodologies. The journal is based in Australia, at 111 River St, Hoboken, NJ, and invites submissions that push the boundaries of current knowledge in this critical area of healthcare.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Empowering breakthroughs at the intersection of technology and cancer treatment.
Publisher: SAGE PUBLICATIONS INCISSN: 1533-0346Frequency: 1 issue/year

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, published by SAGE Publications Inc, is a leading open-access journal dedicated to the intersection of technology and oncology. Since its inception in 2002 and with an impactful transition to open access in 2018, it has garnered attention for its commitment to disseminating groundbreaking research that explores innovative methodologies and technologies in cancer diagnostics and therapeutics. With ISSN 1533-0346 and E-ISSN 1533-0338, the journal is highly relevant in the fields of Cancer Research (Q3), Medicine (Q2), and Oncology (Q3), as indicated by its 2023 category quartiles. Its Scopus rankings further highlight its position within the research community, standing at #186 out of 404 in Medicine and #141 out of 230 in Cancer Research. Through a carefully curated selection of articles, this journal aims to bridge the gap between technological advancement and clinical application, providing a vital resource for researchers, healthcare professionals, and students striving to improve cancer treatment outcomes.

Journal of Contemporary Brachytherapy

Pioneering advancements in brachytherapy for global health.
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1689-832XFrequency: 6 issues/year

Journal of Contemporary Brachytherapy, published by TERMEDIA PUBLISHING HOUSE LTD, is a distinguished open-access journal dedicated to advancing the field of brachytherapy within the oncology and radiology domains. Since its inception in 2009, the journal has provided a platform for researchers, clinicians, and students to share innovative findings, cutting-edge techniques, and clinical experiences, contributing significantly to evidence-based practices in cancer treatment. With an ISSN of 1689-832X and E-ISSN 2081-2841, the journal has established its presence globally, and it is indexed in Scopus, achieving a commendable standing among its peers—with rankings of #196 in Radiology, Nuclear Medicine, and Imaging and #260 in Oncology for 2023. Notably, it holds a Q3 quartile classification, reflecting its emerging influence in these critical fields. The journal is committed to open science, ensuring that research is accessible to a wide audience, which is particularly vital for the ongoing development of methodologies and the implementation of best practices in brachytherapy. Exploring topics from the technical aspects of brachytherapy procedures to patient management strategies, the Journal of Contemporary Brachytherapy is an essential resource for those looking to stay at the forefront of oncological advancements.

Physics & Imaging in Radiation Oncology

Pioneering Insights at the Intersection of Physics and Oncology
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Physics & Imaging in Radiation Oncology is a premier journal dedicated to advancing the interdisciplinary field of radiation oncology through innovative research and imaging technologies. Published by Elsevier, this open-access journal has made its mark since its inception in 2017, ensuring that groundbreaking findings are accessible to a broad audience. With a strong focus on the integration of physics, imaging techniques, and oncology, the journal occupies esteemed positions in the academic landscape, ranking in the top quartile for Radiation and Radiology, Nuclear Medicine and Imaging as of 2023. The journal serves as a platform for researchers, professionals, and students to share insights and foster collaboration, ultimately improving patient outcomes through enhanced imaging and treatment modalities. Based in Ireland and operating from Radarweg 29, 1043 NX Amsterdam, Netherlands, the journal aims to bridge the gap between theoretical physics and practical applications in clinical settings.

CLINICAL ONCOLOGY

Transforming Patient Outcomes with Pioneering Oncology Studies
Publisher: ELSEVIER SCIENCE LONDONISSN: 0936-6555Frequency: 6 issues/year

Clinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.

Nature Reviews Clinical Oncology

Transforming Cancer Research into Practice
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Radiation Oncology

Connecting global experts to enhance radiotherapy practices.
Publisher: BMCISSN: Frequency: 1 issue/year

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

Future Oncology

Leading the charge in cancer research innovation.
Publisher: FUTURE MEDICINE LTDISSN: 1479-6694Frequency: 40 issues/year

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

STRAHLENTHERAPIE UND ONKOLOGIE

Empowering professionals with cutting-edge insights.
Publisher: SPRINGER HEIDELBERGISSN: 0179-7158Frequency: 12 issues/year

STRAHLENTHERAPIE UND ONKOLOGIE is an esteemed journal published by Springer Heidelberg, focusing on critical advancements and research in the fields of Oncology and Radiology. Established in 1986, this journal has carved its niche within the scientific community, ranking in the Q1 category for Radiology, Nuclear Medicine and Imaging, and Q2 for Oncology as of 2023. With an ISSN of 0179-7158 and E-ISSN 1439-099X, it serves as an essential resource for researchers, professionals, and students dedicated to the complexities of cancer treatment and radiation therapy. While the journal operates under a subscription model, its broad international readership values its rigorous peer-review process and comprehensive coverage of pivotal studies. STRAHLENTHERAPIE UND ONKOLOGIE continues to enhance its impact in the domains of oncology and radiology, as evidenced by its commendable Scopus rankings, including a 76th percentile in Radiology and a 65th percentile in Oncology. Its commitment to disseminating innovative research solidifies its role as a cornerstone in the ongoing quest to improve patient care and therapeutic techniques.

ONCOLOGY

Advancing cancer research through impactful insights.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.